Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
BUZZ-Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead ** Shares of Vir Biotechnology VIR.O rise 11.7% to $11.85 premarket
** Co inks collaboration and license agreement with Gilead GILD.O for three candidates targeting selected solid tumor-associated antigens
** VIR will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, and has the potential to receive up to $1.74 billion in further milestones, along with tiered royalties on net sales
** VIR is responsible for discovery, design and optimization, while Gilead will have an exclusive license to develop and commercialize the three T-cell engagers built on Vir's platform
** T-cell engagers are powerful anti-tumor agents designed to direct the immune system to destroy cancer cells
** Separately, cos also entered a stock purchase agreement under which GILD will buy about 1.77 million Vir shares at $14.16 each, for a total investment of roughly $25 million
** Up to last close, VIR stock up ~76% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO